Whole organ and tissue reconstruction in thoracic regenerative surgery

Mayo Clinic Proceedings

Volumn 88, Issue 10, 2013, Pages 1151-1166

  Lim, Mei Ling ^a   Jungebluth, Philipp ^a   Ajalloueian, Fatemeh ^a   Friedrich, Linda Helen ^a   Gilevich, Irina ^a,b   Grinnemo, Karl Henrik ^a   Gubareva, Elena ^a,b   Haag, Johannes C ^a   Lemon, Greg ^a   Sjöqvist, Sebastian ^a   Caplan, Arthur L ^c   Macchiarini, Paolo ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KUBAN STATE MEDICAL UNIVERSITY   (Russian Federation)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE SCAFFOLD;

ALLOTRANSPLANTATION; ARTICLE; BIOENGINEERING; BIOREACTOR; ESOPHAGUS DISEASE; HEART DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMATION RETRIEVAL; MEDICAL ETHICS; MEDLINE; NONHUMAN; ORGAN DONOR; ORGAN ENGINEERING; ORGAN TRANSPLANTATION; REGENERATIVE SURGERY; RESPIRATORY FAILURE; SURGERY; THORAX DISEASE; THORAX SURGERY; TISSUE ENGINEERING; TISSUE TRANSPLANTATION;

EID: 84888635917     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.03.011     Document Type: Review

References (100)

1. World Health Organization. World Health Statistics 2012. Geneva, Switzerland: World Health Organization; 2012. EN-WHS2012-Full.pdf (application/pdf Object). http://www.who.int/gho/publications/world-health- statistics/EN-WHS2012-Full.pdf. Accessed September 1, 2012.
2. Bloom DE, Cafiero ET, Jané-Llopis E, et al. The Global Economic Burden of Noncommunicable Diseases. Geneva, Switzerland: World Economic Forum; 2011. http://www3.weforum.org/docs/WEF-Harvard-HE- GlobalEconomicBurdenNonCommunicableDiseases-2011.pdf. Accessed September 1, 2012.
3. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137-1146.
4. Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194-202.
5. Lund LH, Mancini D. Heart failure in women. Med Clin North Am. 2004;88(5):1321-1345, xii.
6. Deng MC. Orthotopic heart transplantation: highlights and limitations. Surg Clin North Am. 2004;84(1):243-255.
7. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007;116(5):497-505.
8. The Hastings Center. Projected costs of chronic diseases. Health Care Cost Monitor. http://healthcarecostmonitor.thehastingscenter.org/kimberlyswartz/ projected-costs-of-chronic-diseases/. Accessed September 1, 2012.
9. World Health Organization. Global Status Report on Noncommunicable Diseases 2010. Geneva, Switzerland: World Health Organization; 2010. http://www.who.int/nmh/publications/ncd-report-full-en.pdf. Accessed September 1, 2012.
10. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532-555
11. Wallis JM, Borg ZD, Daly AB, et al. Comparative assessment of detergent-based protocols for mouse lung de-cellularization and re-cellularization. Tissue Eng Part C Methods. 2012;18(6): 420-432.
12. Macchiarini P, Jungebluth P, Go T, et al. Clinical transplantation of a tissue-engineered airway. Lancet. 2008;372(9655): 2023-2030.
13. Conconi MT, De Coppi P, Di Liddo R, et al. Tracheal matrices, obtained by a detergent-enzymatic method, support in vitro the adhesion of chondrocytes and tracheal epithelial cells. Transpl Int. 2005;18(6):727-734.
14. Macchiarini P, Walles T, Biancosino C, Mertsching H. First human transplantation of a bioengineered airway tissue. J Thorac Cardiovasc Surg. 2004;128(4):638-641.
15. Ott HC, Clippinger B, Conrad C, et al. Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med. 2010;16(8):927-933.
16. Schmidt CE, Baier JM. Acellular vascular tissues: natural biomaterials for tissue repair and tissue engineering. Biomaterials. 2000;21(22):2215-2231.
17. Baiguera S, Jungebluth P, Burns A, et al. Tissue engineered human tracheas for in vivo implantation. Biomaterials. 2010; 31(34):8931-8938.
18. Baiguera S, Gonfiotti A, Jaus M, et al. Development of bioengineeredhuman larynx. Biomaterials. 2011;32(19):4433-4442.
19. Bonfield TL, Koloze M, Lennon DP, Zuchowski B, Yang SE, Caplan AI. Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model. Am J Physiol Lung Cell Mol Physiol. 2010;299(6):L760- L770.
20. Chong PP, Selvaratnam L, Abbas AA, Kamarul T. Human peripheral blood derived mesenchymal stem cells demonstrate similar characteristics and chondrogenic differentiation potential to bone marrow derived mesenchymal stem cells. J Orthop Res. 2012;30(4):634-642.
21. MaX, Che N, Gu Z, et al. Allogenic mesenchymal stem cell transplantation ameliorates nephritis in lupus mice via inhibition of B-cell activation [published online ahead of print October 31, 2012]. Cell Transplant. doi: 10.3727/ 096368912X658692.
22. Wang D, Zhang H, Liang J, et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years experience [published online ahead of print October 31, 2012]. Cell Transplant. http://dx.doi.org/10.3727/096368912X658719.
23. Jungebluth P, Bader A, Baiguera S, et al. The concept of in vivo airway tissue engineering. Biomaterials. 2012;33(17):4319-4326.
24. AsnaghiMA, Jungebluth P, RaimondiMT, et al.Adouble-chamber rotating bioreactor for the development of tissue-engineered hollow organs: from concept to clinical trial. Biomaterials. 2009; 30(29):5260-5269.
25. Petersen TH, Calle EA, Zhao L, et al. Tissue-engineered lungs for in vivo implantation. Science. 2010;329(5991):538-541.
26. Hoch M, Fischer P, Stapel B, et al. Erythropoietin preserves the endothelial differentiation capacity of cardiac progenitor cells and reduces heart failure during anticancer therapies. Cell Stem Cell. 2011;9(2):131-143.
27. Jungebluth P, Alici E, Baiguera S, et al. Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study. Lancet. 2011;378(9808):1997-2004.
28. Strome M, Stein J, Esclamado R. Laryngeal transplantation and 40-month follow-up. N Engl J Med. 2001;344(22):1676-1679.
29. Fishman JM, Ansari T, Sibbons P, De Coppi P, Birchall MA. Decellularized rabbit cricoarytenoid dorsalis muscle for laryngeal regeneration. Ann Otol Rhinol Laryngol. 2012;121(2): 129-138.
30. Grillo HC. Tracheal replacement: a critical review. Ann Thorac Surg. 2002;73(6):1995-2004.
31. Walles T, Giere B, Hofmann M, et al. Experimental generation of a tissue-engineered functional and vascularized trachea. J Thorac Cardiovasc Surg. 2004;128(6):900-906.
32. Go T, Jungebluth P, Baiguero S, et al. Both epithelial cells and mesenchymal stem cell-derived chondrocytes contribute to the survival of tissue-engineered airway transplants in pigs. J Thorac Cardiovasc Surg. 2010;139(2):437-443.
33. Macchiarini P, Jungebluth P, Go T, et al. Clinical transplantation of a tissue-engineered airway. Lancet. 2008;372(9655): 2023-2030.
34. Elliott MJ, De Coppi P, Speggiorin S, et al. Stem-cell-based, tissue engineered tracheal replacement in a child: a 2-year follow-up study. Lancet. 2012;380(9846):994-1000.
35. Rose KG, Sesterhenn K, Wustrow F. Tracheal allotransplantation in man. Lancet. 1979;1(8113):433.
36. Delaere P, Vranckx J, Verleden G,De Leyn P, Van Raemdonck D. Tracheal allotransplantation after withdrawal of immunosuppressive therapy. N Engl J Med. 2010;362(2):138-145.
37. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662-1668.
38. Huh D, Leslie DC, Matthews BD, et al. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci Transl Med. 2012;4(159): 159ra147.
39. Bonvillain RW, Danchuk S, Sullivan DE, et al. A nonhuman primate model of lung regeneration: detergent-mediated decellularization and initial in vitro recellularization with mesenchymal stem cells. Tiss Eng Part A. 2012;18(23-24):2437-2452.
40. Booth AJ, Hadley R, Cornett AM, et al. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med. 2012; 186(9):866-876.
41. Rouvelas I, Lagergren J. The impact of volume on outcomes after oesophageal cancer surgery. ANZ J Surg. 2010;80(9):634-641.
42. Teoh AYB, Chiu PWY, Yu Ngo DK, Wong SKH, Lau JYW, Ng EKW. Outcomes of endoscopic submucosal dissection versus endoscopic mucosal resection in management of superficial squamous esophageal neoplasms outside Japan. J Clin Gastroenterol. 2010;44(9):190-194.
43. Tan B, Wei R-Q, Tan M-Y, et al. Tissue engineered esophagus by mesenchymal stem cell seeding for esophageal repair in a canine model. J Surg Res. 2013;182(1):40-48.
44. Jönsson L, Gatzinsky V, Jennische E, Johansson C, Nannmark U, Friberg LG. Piglet model for studying esophageal regrowth after resection and interposition of a silicone stented small intestinal submucosa tube. Eur Surg Res. 2011; 46(4):169-179.
45. Doede T, Bondartschuk M, Joerck C, Schulze E, Goernig M. Unsuccessful alloplastic esophageal replacement with porcine small intestinal submucosa. Artif Organs. 2009;33(4):328-333.
46. Badylak S, Hoppo T, Gilbert TW, Davison JM, Jobe BA. Esophageal preservation in five male patients after endoscopic innerlayer circumferential resection in the setting of superficial cancer: a regenerative medicine approach with a biologic scaffold. Tiss Eng Part A. 2011;17(11-12):1643-1650.
47. Ohki T, Yamato M,Ota M, et al. Preventionof esophageal stricture after endoscopic submucosal dissection using tissue-engineered cell sheets. Gastroenterology. 2012;143(3):582-588.e2.
48. Bhrany AAD, Beckstead BBL, Lang TCT, Farwell DG, Giachelli CM, Ratner BD. Development of an esophagus acellular matrix tissue scaffold. Tissue Eng. 2006;12(2):319-330.
49. Ozeki M, Narita Y, Kagami H, et al. Evaluation of decellularized esophagus as a scaffold for cultured esophageal epithelial cells. J Biomed Mater Res A. 2006;79(4):771-778.
50. Marzaro M, Vigolo S. In vitro and in vivo proposal of an artificial esophagus. J Biomed Mater Res A. 2006;77(4):795-801.
51. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410(6829): 701-705.
52. Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004;428(6983):664-668.
53. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004; 428(6983):668-673.
54. Nygren JM, Jovinge S, Breitbach M, et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med. 2004;10(5):494-501.
55. Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306(19): 2110-2119.
56. Laflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. 2007;25(9):1015-1024.
57. Miyahara Y, Nagaya N, Kataoka M, et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med. 2006;12(4):459-465.
58. Genead R, Fischer H, Hussain A, et al. Ischemia-reperfusion injury and pregnancy initiate time-dependent and robust signs of up-regulation of cardiac progenitor cells. PloS One. 2012; 7(5):e36804.
59. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):763-776.
60. Chugh AR, Beache GM, Loughran JH, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation. 2012;126(11, suppl 1):S54-S64.
61. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report 2007. J Heart Lung Transplant. 2007;26(8):769-781.
62. Kallenbach K, Sorrentino S, Mertsching H, et al. A novel smallanimal model for accelerated investigation of tissueengineered aortic valve conduits. Tiss Eng Part C Methods. 2010;16(1):41-50.
63. Baraki H, Tudorache I, Braun M, et al. Orthotopic replacement of the aortic valve with decellularized allograft in a sheep model. Biomaterials. 2009;30(31):6240-6246.
64. da Costa FDA, Costa ACBA, Prestes R, et al. The early and midterm function of decellularized aortic valve allografts. Ann Thoracic Surg. 2010;90(6):1854-1860.
65. Cebotari S, Tudorache I, Ciubotaru A, et al. Use of fresh decellularized allografts for pulmonary valve replacement may reduce the reoperation rate in children and young adults: early report. Circulation. 2011;124(11, suppl):S115-S123.
66. Rüffer A, Purbojo A, Cicha I, et al. Early failure of xenogenous de-cellularised pulmonary valve conduits: a word of caution. Eur J Cardiothorac Surg. 2010;38(1):78-85.
67. Ghanbari H, Kidane AG, Burriesci G, Ramesh B, Darbyshire A, Seifalian AM. The anti-calcification potential of a silsesquioxane nanocomposite polymer under in vitro conditions: potential material for synthetic leaflet heart valve. Acta Biomater. 2010;6(11):4249-4260.
68. Driessen NJB, Mol A, Bouten CVC, Baaijens FPT. Modeling the mechanics of tissue-engineered human heart valve leaflets. J Biomech. 2007;40(2):325-334.
69. Ziegelmueller JA, Zaenkert EK, Schams R, et al. Optical monitoring during bioreactor conditioning of tissue-engineered heart valves. ASAIO J. 2010;56(3):228-231.
70. Hong H, Dong N, Shi J, et al. Fabrication of a novel hybrid heart valve leaflet for tissue engineering: an in vitro study. Artif Organs. 2009;33(7):554-558.
71. Dijkman PE, Driessen-Mol A, Frese L, Hoerstrup SP, Baaijens FPT. Decellularized homologous tissue-engineered heart valves as off-the-shelf alternatives to xeno- and homografts. Biomaterials. 2012;33(18):4545-4554.
72. Maish MS. The diaphragm. Surg Clin North Am. 2010;90(5): 955-968.
73. Loff S, Wirth H, Jester I, et al. Implantation of a cone-shaped double-fixed patch increases abdominal space and prevents recurrence of large defects in congenital diaphragmatic hernia. J Pediatr Surg. 2005;40(11):1701- 1705.
74. Mitchell IC, Garcia NM, Barber R, Ahmad N, Hicks BA, Fischer AC. Permacol: a potential biologic patch alternative in congenital diaphragmatic hernia repair. J Pediatr Surg. 2008;43(12):2161-2164.
75. Menon NG, Rodriguez ED, Byrnes CK, Girotto JA, Goldberg NH, Silverman RP. Revascularization of human acellular dermis in full-thickness abdominal wall reconstruction in the rabbit model. Ann Plas Surg. 2003;50(5):523-527.
76. Sandoval JA, Lou D, Engum SA, et al. The whole truth: comparative analysis of diaphragmatic hernia repair using 4-ply vs 8-ply small intestinal submucosa in a growing animal model. J Pediatr Surg. 2006;41(3):518-523.
77. Laituri CA, Garey CL, Valusek PA, et al. Outcome of congenital diaphragmatic hernia repair depending on patch type [published online ahead of print November 5, 2010]. Eur J Pediatr Surg. doi: 10.1055/s-0030-1268456.
78. Tsao K, Lally KP. Innovations in the surgical management of congenital diaphragmatic hernia. Clin Perinatol. 2012;39(2): 363-374.
79. Joshi SB, Sen S, Chacko J, Thomas G, Karl S. Abdominal muscle flap repair for large defects of the diaphragm. Pediatr Surg Int. 2005;21(8):677-680.
80. Sydorak RM, Hoffman W, Lee H, et al. Reversed latissimus dorsi muscle flap for repair of recurrent congenital diaphragmatic hernia. J Pediatr Surg. 2003;38(3):296-300.
81. Samarakkody U, Klaassen M, Nye B. Reconstruction of congenital agenesis of hemidiaphragm by combined reverse latissimus dorsi and serratus anterior muscle flaps. J Pediatr Surg. 2001;36(11):1637-1640.
82. Bekdash B, Singh B, Lakhoo K. Recurrent late complications following congenital diaphragmatic hernia repair with prosthetic patches: a case series. J Med Case Rep. 2009;3:7237.
83. Rossi CA, Pozzobon M, Ditadi A, et al. Clonal characterization of rat muscle satellite cells: proliferation, metabolism and differentiation define an intrinsic heterogeneity. PloS One. 2010;5(1):e8523, doi: 10.1371/journal.pone. 0008523.
84. De Coppi P, Bartsch G, Siddiqui MM, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol. 2007;25(1):100-106.
85. Fuchs JR, Kaviani A, Oh J-T, et al. Diaphragmatic reconstruction with autologous tendon engineered from mesenchymal amniocytes. J Pediatr Surg. 2004;39(6):834-838.
86. Ott HC, Matthiesen TS, Goh S-K, et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med. 2008;14(2):213-221.
87. Vunjak-Novakovic G, Tandon N, Godier A, et al. Challenges in cardiac tissue engineering. Tissue Eng Part B Rev. 2010; 16(2):169-187.
88. Nikolaev NI, Obradovic B, Versteeg HK, Lemon G, Williams DJ. A validated model of GAG deposition, cell distribution, and growth of tissue engineered cartilage cultured in a rotating bioreactor. Biotechnol Bioeng. 2010;105(4): 842-853.
89. Chung CA, Chen CW, Chen CP, Tseng CS. Enhancement of cell growth in tissue-engineering constructs under direct perfusion: modeling and simulation. Biotechnol Bioeng. 2007; 97(6):1603-1616.
90. Daly AB, Wallis JM, Borg ZD, et al. Initial binding and recellularization of decellularized mouse lung scaffolds with bone marrow-derived mesenchymal stromal cells. Tissue Eng Part A. 2012;18(1-2):1-16.
91. Shaari CM, Farber D, Brandwein MS, Gannon P, Urken ML. Characterizing the antigenic profile of the human trachea: implications for tracheal transplantation. Head Neck. 1998;20(6): 522-527.
92. Medzhitov R, Janeway CA. How does the immune system distinguish self from nonself? Semin Immunol. 2000;12(3): 185-188.
93. Cooper DK, Good AH, Koren E, et al. Identification of alphagalactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transpl Immun. 1993;1(3):198-205.
94. Gilbert TW, Freund JM, Badylak SF. Quantification of DNA in biologic scaffold materials. J Surg Res. 2009;152(1):135-139.
95. Marzaro M, Conconi MT, Perin L, et al. Autologous satellite cell seeding improves in vivo biocompatibility of homologous muscle acellular matrix implants. Int J Mol Med. 2002;10(2): 177-182.
96. Meyer SR, Chiu B, Churchill TA, Zhu L, Lakey JRT, Ross DB. Comparison of aortic valve allograft decellularization. Transplant. 2006;82(10):1286-1290.
97. Keane TJ, Londono R, Turner NJ, Badylak SF. Consequences of ineffective decellularization of biologic scaffolds on the host response. Biomaterials. 2012;33(6):1771-1781.
98. Brown BN, Valentin JE, Stewart-Akers AM, McCabe GP, Badylak SF. Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials. 2009;30(8):1482-1491.
99. Henderson GE, Churchill LR, Davis AM, et al. Clinical trials and medical care: defining the therapeutic misconception. PLoS Med. 2007;4(11):e324, doi: 10.1371/journal.pmed. 0040324.
100. Caplan AL, Levine B. Hope, hype and help: ethically assessing the growing market in stem cell therapies. Am J Bioethics. 2010; 10(5):24-25.